Roche Pharmaceutical Development and Sales Overview
Roche Group development pipeline
Phase III (10 NMES + 46 Als)
Kadcyla + T
2L+ HER-2+ PD-L1+ mBC
RG3648
Xolair
RG3502
Kadcyla + T
HER-2+ eBC high-risk
RG6354
zinpentraxin alfa (PRM-151)
RG6026
glofitamab+chemo
2L+ DLBCL
Gazyva
tiragolumab + T
tiragolumab +T
RG6058
tiragolumab + T
tiragolumab + T
tiragolumab + T
1L PD-L1+ NSCLC
1L esophageal cancer
locally advanced esophageal cancer
stage III unresectable 1L NSCLC
1L non-squamous NSCLC
RG7159
Gazyva
Gazyva
food allergy
lupus nephritis
membranous nephropathy
systemic lupus erythematosus
RG6013
Hemlibra¹
IPF
RG6026
glofitamab²
RG6396
Gavreto1
RG7596
Polivy³
RG7828
Lunsumio (mosunetuzumab)³
Xofluza
RG6152
Xofluza
gantenerumab
RG1450
crovalimab*
RG6107
crovalimab
PNH
aHUS
gantenerumab
Ocrevus higher dose
RG1594
RG6114
RG6171
inavolisib (mPI3K alpha inh)
giredestrant (SERD)
giredestrant (SERD)
1L HR+ MBC
Ocrevus SC
1L ER+/HER2- MBC
RG3625
TNKase
influenza, pediatric (0-1 year)
influenza direct transmission
prodromal to mild Alzheimer's
preclinical Alzheimer's
RMS & PPMS
RMS & PPMS
stroke
RG6321
Susvimo (PDS)1
RG6152
Xofluza1
RG56413+
Ronapreve²
RG6412
RG1569
Actemra³
RG7916
Evrysdi¹
Roche
Registration US & EU (3 NMES + 7Als)
mild to moderate hemophilia A
3L+ DLBCL
RET+ MTC, TC
1L DLBCL
3 L+ FL
WAMD
influenza, pediatric
SARS-CoV-2 hospitalised
COVID-19 pneumonia
SMA pediatric <2months
ER+ BC adj
RG6042
tominersen
RG7440
RG7446
giredestrant (SERD) + Phesgo
ipatasertib + abiraterone
Tecentriq+platinum chemo
Tecentriq
Tecentriq+cabozantinib
Tecentriq+cabozantinib
T± chemo
T + capecitabine or carbo/gem
T + paclitaxel
RG6168
1L ER+/HER2+ BC
Enspryng
Huntington's
myasthenia gravis
RG6168
1L CRPC
NSCLC periadj
NMIBC, high risk
Enspryng
MOG-AD
2Filed in EU
RG6168
Enspryng
autoimmune encephalitis
1Approved in US, filed in EU
3Approved in EU, filed in US
RG6356
delandistrogene moxeparvovec (SRP-9001)
DMD
RG7845
fenebrutinib
RMS
RCC adv
RG7845
fenebrutinib
PPMS
2L NSCLC
T + Avastin
T± chemo
SCCHN adj
1L TNBC
TNBC adj
HCC adj
1L MUC
Susvimo (PDS)
DME
T=Tecentriq
PDS-Port Delivery System with ranibizumab
*First filed in China
RG6321
Susvimo (PDS)
DR
RG7716
Susvimo (PDS)
Vabysmo (faricimab)
Vabysmo (faricimab)
WAMD, 36-week
BRVO
CRVO
2L NSCLC
RG7601
RG7828
RG7853
Tecentriq SC
Tecentriq
T+ lurbinectedin
Venclexta
Venclexta + azacitidine
ctDNA+ high-risk MIBC
1L maintenance SCLC
r/r MM t(11:14)
Lunsumio (mosunetuzumab) + lenalidomide
Lunsumio (mosunetuzumab) + Polivy
Alecensa
New Molecular Entity (NME)
Additional Indication (Al)
Oncology/Hematology
1L MDS
2L+ FL
Immunology
Infectious Diseases
2L+ DLBCL
ALK+ NSCLC adj
Status as of October 18, 2022
Metabolism
Neuroscience
Ophthalmology
Other
54View entire presentation